Table 1.
Characteristics of the study population
| FEC-T | PTC | p-value* | |
|---|---|---|---|
| (N = 193) | (N = 196) | ||
| Age (years) | 0.982 | ||
| Mean (SD) | 49.2 (9.50) | 49.2 (10.5) | |
| Median [Min, Max] | 49.0 [25.0, 73.0] | 48.0 [22.0, 74.0] | |
| HR status | 1.000 | ||
| Negative | 76 (39.4%) | 77 (39.3%) | |
| Positive | 117 (60.6%) | 119 (60.7%) | |
| Grade | 1.000 | ||
| 1-2 | 99 (51.3%) | 100 (51.0%) | |
| 3 | 86 (44.6%) | 87 (44.4%) | |
| Missing | 8 (4.1%) | 9 (4.6%) | |
| cT-stage | 0.494 | ||
| cT0-2 | 127 (65.8%) | 137 (69.9%) | |
| cT3-4 | 65 (33.7%) | 59 (30.1%) | |
| Missing | 1 (0.5%) | 0 (0%) | |
| cN-stage | 0.456 | ||
| cN0 | 77 (39.9%) | 70 (35.7%) | |
| cN+ | 116 (60.1%) | 126 (64.3%) | |
| HER2 IHC | 0.409 | ||
| 1-2+ | 15 (7.8%) | 21 (10.7%) | |
| 3+ | 176 (91.2%) | 173 (88.3%) | |
| Missing | 2 (1.0%) | 2 (1.0%) | |
| Histology | 0.708 | ||
| Ductal | 173 (89.6%) | 178 (90.8%) | |
| Lobular | 9 (4.7%) | 6 (3.1%) | |
| Other | 11 (5.7%) | 12 (6.1%) | |
| TILs (%) | 0.47 | ||
| Median [Min, Max] | 7.07 [1.00, 85.0] | 7.07 [1.00, 92.5] |
FEC-TP 5-Fluoruracil, Epirubicin, Cyclophosfamide, Trastuzumab, Pertuzumab, PTC-P Paclitaxel, Trastuzumab, Carboplatin, Pertuzumab, HR status hormone receptor status, cN0 clinical node negative, cN+ clinical node positive, HER2 IHC HER2 immunohistochemistry scoring, TILs Tumor Infiltrating Lymphocytes, N number, SD standard deviation, Min minimum, Max maximum.
*P-values are from chi-square tests for categorical variables, t-test for age and Wilcoxon test for TILs.